| Year |
Citation |
Score |
| 2020 |
Holland-Tummillo KM, Shoudy LE, Steiner D, Kumar S, Rosa SJ, Namjoshi P, Singh A, Sellati TJ, Gosselin EJ, Hazlett KR. Autotransporter-Mediated Display of Complement Receptor Ligands by Gram-Negative Bacteria Increases Antibody Responses and Limits Disease Severity. Pathogens (Basel, Switzerland). 9. PMID 32422907 DOI: 10.3390/Pathogens9050375 |
0.484 |
|
| 2020 |
Kumar S, Sunagar R, Gosselin EJ. Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection. Vaccines. 8. PMID 32340134 DOI: 10.3390/Vaccines8020193 |
0.519 |
|
| 2019 |
Nelson NLJ, Zajd CM, Lennartz MR, Gosselin EJ. Fcγ receptors and toll-like receptor 9 synergize to drive immune complex-induced dendritic cell maturation. Cellular Immunology. 103962. PMID 31582169 DOI: 10.1016/J.Cellimm.2019.103962 |
0.413 |
|
| 2019 |
Kumar S, Sunagar R, Gosselin E. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants. Frontiers in Immunology. 10: 1144. PMID 31191528 DOI: 10.3389/Fimmu.2019.01144 |
0.437 |
|
| 2018 |
Sunagar R, Kumar S, Namjoshi P, Rosa SJ, Hazlett KRO, Gosselin EJ. Evaluation of an outbred mouse model for Francisella tularensis vaccine development and testing. Plos One. 13: e0207587. PMID 30533047 DOI: 10.1371/Journal.Pone.0207587 |
0.376 |
|
| 2018 |
Sunagar R, Kumar S, Rosa SJ, Hazlett KRO, Gosselin EJ. Differential Cultivation of Influences Live Vaccine Protective Efficacy by Altering the Immune Response. Frontiers in Immunology. 9: 1594. PMID 30042767 DOI: 10.3389/Fimmu.2018.01594 |
0.439 |
|
| 2017 |
Holland KM, Rosa SJ, Kristjansdottir K, Wolfgeher D, Franz BJ, Zarrella TM, Kumar S, Sunagar R, Singh A, Bakshi CS, Namjoshi P, Barry EM, Sellati TJ, Kron SJ, Gosselin EJ, et al. Differential Growth of Francisella tularensis, Which Alters Expression of Virulence Factors, Dominant Antigens, and Surface-Carbohydrate Synthases, Governs the Apparent Virulence of Ft SchuS4 to Immunized Animals. Frontiers in Microbiology. 8: 1158. PMID 28690600 DOI: 10.3389/Fmicb.2017.01158 |
0.387 |
|
| 2017 |
Kumar S, Sunagar R, Pham G, Gosselin EJ, Nalin D. Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine. Vaccine. PMID 28069362 DOI: 10.1016/J.Vaccine.2016.12.035 |
0.391 |
|
| 2016 |
Kumar S, Sunagar R, Pham G, Franz BJ, Rosa SJ, Hazlett KR, Gosselin EJ. Differential Cultivation of Francisella tularensis Induces Changes in the Immune Response to and Protective Efficacy of Whole Cell-Based Inactivated Vaccines. Frontiers in Immunology. 7: 677. PMID 28119692 DOI: 10.3389/Fimmu.2016.00677 |
0.422 |
|
| 2016 |
Sunagar R, Kumar S, Franz BJ, Gosselin EJ. Vaccination evokes gender-dependent protection against tularemia infection in C57BL/6Tac mice. Vaccine. PMID 27182819 DOI: 10.1016/J.Vaccine.2016.04.054 |
0.336 |
|
| 2015 |
Babadjanova Z, Wiedinger K, Gosselin EJ, Bitsaktsis C. Targeting of a Fixed Bacterial Immunogen to Fc Receptors Reverses the Anti-Inflammatory Properties of the Gram-Negative Bacterium, Francisella tularensis, during the Early Stages of Infection. Plos One. 10: e0129981. PMID 26114641 DOI: 10.1371/Journal.Pone.0129981 |
0.457 |
|
| 2015 |
Franz BJ, Li Y, Bitsaktsis C, Iglesias BV, Pham G, Sunagar R, Kumar S, Gosselin EJ. Downmodulation of vaccine-induced immunity and protection against the intracellular bacterium Francisella tularensis by the inhibitory receptor FcγRIIB. Journal of Immunology Research. 2015: 840842. PMID 25961064 DOI: 10.1155/2015/840842 |
0.439 |
|
| 2015 |
Suresh RV, Ma Z, Sunagar R, Bhatty V, Banik S, Catlett SV, Gosselin EJ, Malik M, Bakshi CS. Preclinical testing of a vaccine candidate against tularemia. Plos One. 10: e0124326. PMID 25897786 DOI: 10.1371/Journal.Pone.0124326 |
0.356 |
|
| 2015 |
Bitsaktsis C, Babadjanova Z, Gosselin EJ. In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model. Infection and Immunity. 83: 77-89. PMID 25312957 DOI: 10.1128/Iai.02289-14 |
0.491 |
|
| 2014 |
Pham GH, Iglesias BV, Gosselin EJ. Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells. Vaccine. 32: 5212-20. PMID 25068496 DOI: 10.1016/J.Vaccine.2014.07.050 |
0.471 |
|
| 2013 |
Iglesias BV, Bitsaktsis C, Pham G, Drake JR, Hazlett KR, Porter K, Gosselin EJ. Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen. Immunology and Cell Biology. 91: 139-48. PMID 23247654 DOI: 10.1038/Icb.2012.66 |
0.402 |
|
| 2013 |
Bitsaktsis C, Wiedinger K, Gosselin EJ. Targeting Cellular Receptors as a Strategy for the Development of New Generation Mucosal Vaccines American Journal of Immunology. 9: 9-25. DOI: 10.3844/Ajisp.2013.9.25 |
0.498 |
|
| 2012 |
Wladis EJ, Iglesias BV, Adam AP, Nazeer T, Gosselin EJ. Toll-like receptors in idiopathic orbital inflammation. Ophthalmic Plastic and Reconstructive Surgery. 28: 273-6. PMID 22689135 DOI: 10.1097/Iop.0B013E3182565C59 |
0.348 |
|
| 2012 |
Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infection and Immunity. 80: 1166-80. PMID 22158740 DOI: 10.1128/Iai.05511-11 |
0.469 |
|
| 2011 |
Periasamy S, Singh A, Sahay B, Rahman T, Feustel PJ, Pham GH, Gosselin EJ, Sellati TJ. Development of tolerogenic dendritic cells and regulatory T cells favors exponential bacterial growth and survival during early respiratory tularemia. Journal of Leukocyte Biology. 90: 493-507. PMID 21724804 DOI: 10.1189/Jlb.0411197 |
0.374 |
|
| 2009 |
Gosselin EJ, Bitsaktsis C, Li Y, Iglesias BV. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Archivum Immunologiae Et Therapiae Experimentalis. 57: 311-23. PMID 19688186 DOI: 10.1007/S00005-009-0040-Y |
0.487 |
|
| 2009 |
Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, Gosselin EJ. Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. Journal of Immunology (Baltimore, Md. : 1950). 182: 4899-909. PMID 19342669 DOI: 10.4049/Jimmunol.0803242 |
0.397 |
|
| 2008 |
Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, Kurkure NV, Metzger DW, Gosselin EJ. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. Journal of Immunology (Baltimore, Md. : 1950). 180: 5548-57. PMID 18390739 DOI: 10.4049/Jimmunol.180.8.5548 |
0.434 |
|
| 2005 |
Gosselin EJ, Gosselin DR, Lotz SA. Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain. Human Immunology. 66: 1039-49. PMID 16386645 DOI: 10.1016/J.Humimm.2005.08.240 |
0.377 |
|
| 2005 |
Adamova E, Walsh MC, Gosselin DR, Hale K, Preissler MT, Graziano RF, Gosselin EJ. Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunological Investigations. 34: 417-29. PMID 16304730 DOI: 10.1080/08820130500265372 |
0.764 |
|
| 2005 |
Preissler MT, Kaiser L, Drake JR, Gosselin EJ. Low-level signaling generated by FcgammaRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness. Immunological Investigations. 34: 53-70. PMID 15773572 DOI: 10.1081/1MM-200047385 |
0.748 |
|
| 2005 |
Preissler MT, Kaiser L, Drake JR, Gosselin EJ. Low-level signaling generated by FcγRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness Immunological Investigations. 34: 53-70. DOI: 10.1081/Imm-47385 |
0.742 |
|
| 2003 |
Preissler MT, Walsh MC, Banas JA, Gallagher DJ, Gosselin EJ. Generation of a human IgG3-streptavidin fusion protein. Implications for the inhibition and elimination of auto-reactive B cells. Human Antibodies. 12: 77-92. PMID 14646036 DOI: 10.3233/Hab-2003-12304 |
0.768 |
|
| 2003 |
Jordan RA, Preissler MT, Banas JA, Gosselin EJ. Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation. Clinical and Diagnostic Laboratory Immunology. 10: 339-44. PMID 12738628 DOI: 10.1128/Cdli.10.3.339-344.2003 |
0.736 |
|
| 2003 |
Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ. A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomolecular Engineering. 20: 21-33. PMID 12485681 DOI: 10.1016/S1389-0344(02)00089-8 |
0.762 |
|
| 2003 |
Walsh MC, Banas JA, Mudzinski SP, Preissler MT, Graziano RF, Gosselin EJ. A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcγRI-streptavidin construct and microspheres coated with biotinylated-antigen Biomolecular Engineering. 20: 21-33. DOI: 10.1016/S1389-0344(02)00089-8 |
0.769 |
|
| 2002 |
Goller ME, Kneitz C, Mehringer C, Müller K, Jelley-Gibbs DM, Gosselin EJ, Wilhelm M, Tony HP. Regulation of CD23 isoforms on B-chronic lymphocytic leukemia. Leukemia Research. 26: 795-802. PMID 12127553 DOI: 10.1016/S0145-2126(02)00007-3 |
0.386 |
|
| 2001 |
Plitnick LM, Jordan RA, Banas JA, Jelley-Gibbs DM, Walsh MC, Preissler MT, Gosselin EJ. Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2. Clinical and Diagnostic Laboratory Immunology. 8: 972-9. PMID 11527813 DOI: 10.1128/Cdli.8.5.972-979.2001 |
0.732 |
|
| 1999 |
Jelley-Gibbs DM, Plitnick LM, Gosselin EJ. Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells Human Immunology. 60: 469-478. PMID 10408796 DOI: 10.1016/S0198-8859(99)00023-3 |
0.462 |
|
| 1999 |
Murad KL, Gosselin EJ, Eaton JW, Scott MD. Stealth Cells: Prevention of Major Histocompatibility Complex Class II-Mediated T-Cell Activation by Cell Surface Modification Blood. 94: 2135-2141. DOI: 10.1182/BLOOD.V94.6.2135 |
0.311 |
|
| 1998 |
Plitnick LM, Banas JA, Jelley-Gibbs DM, O'neil J, Christian T, Mudzinski SP, Gosselin EJ. Inhibition of interleukin-2 by a Gram-positive bacterium, Streptococcus mutans. Immunology. 95: 522-8. PMID 9893040 DOI: 10.1046/j.1365-2567.1998.00631.x |
0.379 |
|
| 1997 |
Fanger NA, Liu C, Guyre PM, Wardwell K, O'Neil J, Guo TL, Christian TP, Mudzinski SP, Gosselin EJ. Activation of human T cells by major histocompatability complex class II expressing neutrophils: Proliferation in the presence of superantigen, but not tetanus toxoid Blood. 89: 4128-4135. PMID 9166855 DOI: 10.1182/Blood.V89.11.4128 |
0.387 |
|
| 1996 |
Liu C, Gosselin EJ, Guyre PM. FcγRII on human B cells can mediate enhanced antigen presentation Cellular Immunology. 167: 188-194. PMID 8603427 DOI: 10.1006/Cimm.1996.0026 |
0.471 |
|
| Show low-probability matches. |